United Therapeutics Announced Full Enrollment Of The TETON 2 Study Of Tyvaso (Treprostinil) Inhalation Solution (Nebulized Tyvaso) For Idiopathic Pulmonary Fibrosis, Top Line Data Expected In The Second Half Of 2025
United Therapeutics Announced Full Enrollment Of The TETON 2 Study Of Tyvaso (Treprostinil) Inhalation Solution (Nebulized Tyvaso) For Idiopathic Pulmonary Fibrosis, Top Line Data Expected In The Second Half Of 2025
美國聯合醫療宣佈完成特翼嗍2號試驗(使用Tyvaso(曲前列素)霧化吸入的Tyvaso治療溶液)治療特發性肺纖維化的患者招募，預計在2025年下半年公佈首席數據。
United Therapeutics Announced Full Enrollment Of The TETON 2 Study Of Tyvaso (Treprostinil) Inhalation Solution (Nebulized Tyvaso) For Idiopathic Pulmonary Fibrosis, Top Line Data Expected In The Second Half Of 2025
美國聯合醫療宣佈完成特翼嗍2號試驗(使用Tyvaso(曲前列素)霧化吸入的Tyvaso治療溶液)治療特發性肺纖維化的患者招募，預計在2025年下半年公佈首席數據。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。